Meme Kanserinde Sık Kullanılan Kemoterapötiklerin İlaç -İlaç Etkileşimleri ve Önemi
Özet
Son küresel kanser istatistiklerine göre (2020), meme kanseri (BCa) dünyada en sık teşhis edilen kanser türüdür. Kemoterapi, cerrahi ve radyasyonla birlikte, hem sitotoksik (örn. alkilleyici ajanlar, taksanlar, antimetabolitler ve antrasiklinler), hem hormonal hem de hücre döngüsü inhibitor ajanlarını içeren BCa tedavisinin temel dayanağı olmuştur . BCa patogenezinin karmaşıklığı nedeniyle, birden fazla antikanser ilacı içeren polifarmasi, genellikle mono-kemoterapiden daha yüksek yanıt oranlarına gösterilen bu tedavi yaklaşımının ayrılmaz bir parçası olmaya devam etmektedir .Doksorubicin , siklofosfamid , paklitaksel , dosetaksel , karboplatin , kapesitabin , gemsitabin en sık kullanılan kemoterapötik ajanlar olarak bilinmekte , bunların beraber kullanılması, destek tedavisi ajanları ve CYP enzim sistemi inhibitör / aktivatörleri ile etkileşimde yan etki ve toksisiteler meydana gelebilmektedir.
Referanslar
Beijnen JH, Schellens JH. Drug interactions in oncology Lancet Oncol . 5:489-96, 2004.
Yancik R,Ries LAG. Aging and cancer in America. Hematol Oncol Clin North Am 14;17-23,2000.
Karas Jr S. The potential for drug interactions. Ann Emerg Med 10:627- 30,1981.
Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives in comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 19:1147–54, 2001.
Deb S, Hopefl R. Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs. DARU, Journal of Pharmaceutical Sciences. 2023 Dec 1;31(2):95–105.
Khunger A, Estfan B. Chapter 10 - Cardiovascular Toxicities of Chemotherapy. In: Velcheti V, Punekar S, editors. Handbook of Cancer Treatment-Related Symptoms and Toxicities [Internet]. Philadelphia: Elsevier; 2020. p. 93–106. Available from: https://www.sciencedirect.com/science/article/pii/B9780323672412000100
Alexa-Stratulat T, Luca A, Bădescu M, Bohotin CR, Alexa ID. Chapter 2 - Nutritional Modulators in Chemotherapy-Induced Neuropathic Pain. In: Watson RR, Zibadi S, editors. Nutritional Modulators of Pain in the Aging Population [Internet]. Academic Press; 2017. p. 9–33. Available from: https://www.sciencedirect.com/science/article/pii/B9780128051863000023
Bharti AC, Vishnoi K, Singh SM, Aggarwal BB. Chapter 1 - Pathways Linked to Cancer Chemoresistance and Their Targeting by Nutraceuticals. In: Bharti AC, Aggarwal BB, editors. Role of Nutraceuticals in Cancer Chemosensitization [Internet]. Academic Press; 2018. p. 1–30. (Cancer Sensitizing Agents for Chemotherapy; vol. 2). Available from: https://www.sciencedirect.com/science/article/pii/B9780128123737000012
Kayku V. Antimetabolitlerin Etki Mekanizmaları ve Sınıflandırılması. In: Antineoplastik İlaçlar. Akademisyen Kitabevi; 2022. p. 139–44.
Bardal SK, Waechter JE, Martin DS. Chapter 20 - Neoplasia. In: Bardal SK, Waechter JE, Martin DS, editors. Applied Pharmacology [Internet]. Philadelphia: W.B. Saunders; 2011. p. 305–24. Available from: https://www.sciencedirect.com/science/article/pii/B9781437703108000208
Douedi S CMP. anthracycline medications (doxorubicin) uptaded 2023 Aug 8 stat peals publising :2025 jan-available .
Ogino MH TP. cyclophosphamide.(updated 2023 july 3). in StatPearls(ınternet). Treasu island(FL):StatPearls publishing;2025 jan.
Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther [Internet]. 1984;25(1):83–125. Available from: https://www.sciencedirect.com/science/article/pii/0163725884900251
Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Vol. 140, Gynecologic Oncology. Academic Press Inc.; 2016. p. 176–83.
Xiong X, Sui M, Fan W, Kraft AS. Cell-cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol Ther [Internet]. 2007;6(7):1067–73. Available from: https://doi.org/10.4161/cbt.6.7.4323
Awosika AO, Farrar MC, Jacobs TF. paclitaxel ,( updated 2023 nov 18 ) İn : StatPearls (internet ) treasure island (FL) StatPearls publishing ; 2025 jan .
Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis [Internet]. 2011;14(3):192–205. Available from: https://doi.org/10.1038/pcan.2011.23
felix hammann verena GKC ,Michael M, PC. 36th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 24-27 May, 2016, Madrid, Spain. Clin Toxicol. 2016 Apr 20;54(4):344–519.
Cortellini G, Raiteri A, Biagioni B, Liberati S, Lippolis D, Cortellini G, et al. Taxanes hypersensitivity is not a risk factor for severe reactions to SARS-CoV-2 vaccines. Eur Ann Allergy Clin Immunol. 2023 Sep 1;55(5):229–34.
Gligorov G, lotz JP. Preclinical and clinical data of the use of carboplatin in the treatment of breast cancer . cancer treat rev .2004 ; 30(1):31-36).
Milano G et al . DPD deficiency and fluoropyrimidine toxicity, Cancer Chemother Pharmacol.1996.
Hokusai et al. j Clin Oncol, 2008 ; FDA Drug Safety Communication, 2013.
Milano et al. Cancer Chemother Pharmacol, 1996.
Iwamoto T et al. Elevated phenytoin levels caused by capecitabine. Ann pharmacother. 2003.
Sunakawa Y et al. Proton pump inhibitor affects capecitabine efficacy in colorectal cancer . Oncotarget.2016.
Houssami N, Anderson BO. Would the real breast cancer please stand up? A global perspective of breast cancer. Vol. 17, Breast. Churchill Livingstone; 2008. p. 217–9.
Oliveras-Ferraros C et al. Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling .Int J Oncol . 2008 ; 32 (1) : 113 -120.
Fogli S, Danesi R, Gennari A, Donati S, Conte PF, Del Tacca M. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Annals of Oncology [Internet]. 2002 Jun 1;13(6):919–27. Available from: https://doi.org/10.1093/annonc/mdf164
Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Vol. 78, Cancer Chemotherapy and Pharmacology. Springer Verlag; 2016.
Saif MW. Interaction between Gemcitabine and Warfarin Causing Gastrointestinal Bleeding in a Patient with Pancreatic Cancer.
